Health Guide
Healthy Aging
Plain-English summaries: what it is, what it was studied for, safety and regulatory status, plus mixing and dosing charts.
A peptide that prompts the pituitary to release growth hormone.
An experimental four-amino-acid peptide studied for telomeres, aging and circadian rhythms.
A four-amino-acid peptide that targets mitochondria. In September 2025 the FDA granted accelerated approval to Forzinity (elamipretide) for muscle strength in Barth syndrome, a rare genetic disorder.
"191AA" just describes the 191-amino-acid human growth hormone molecule; somatropin is the recombinant prescription version.
A small peptide encoded by mitochondrial DNA and studied for cell survival, metabolism and aging.
An experimental "senolytic" peptide designed to trigger the removal of certain aging (senescent) cells.
An FDA-approved prescription medicine that builds bone in people with osteoporosis at high fracture risk.
An FDA-approved prescription bone-building medicine for osteoporosis in adults at high fracture risk.
A three-amino-acid bioregulator peptide studied for effects on blood-vessel lining cells.
A four-amino-acid bioregulator peptide studied mainly in lab models of chromatin, protein synthesis and digestive enzymes.
A four-amino-acid bioregulator peptide studied in heart-tissue cultures and animals.
A four-amino-acid bioregulator peptide studied in prostate tissue and cellular-aging experiments.
A two-amino-acid synthetic peptide studied in immune-cell and aging research.
A four-amino-acid research peptide studied in airway cells and experimental lung-injury models.
A three-amino-acid bioregulator peptide studied for effects on inflammatory signaling.
A short tripeptide marketed as a liver or digestive "bioregulator." The clearest published experiments involve kidney cells and older rats, not liver disease in people.